Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Anthony Yu, Eva Huang, Momoka Abe, Kang An, Sun-Kyeong Park & Chanhyun Park. (2021) Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 21:3, pages 381-393.
Read now
Read now
Alain Vergnenegre & Christos Chouaid. (2021) Economic analyses of immune-checkpoint inhibitors to treat lung cancer. Expert Review of Pharmacoeconomics & Outcomes Research 21:3, pages 365-371.
Read now
Read now
Na Li, Huanrui Zheng, Bin Zheng, Chaoxin Chen, Hongfu Cai & Maobai Liu. (2020) Economic Evaluations of Immune Checkpoint Inhibitors for Patients with Non-Small Cell Lung Cancer: A Systematic Review. Cancer Management and Research 12, pages 4503-4518.
Read now
Read now
Deirdre Mladsi, Lisa M. Hess, Christine L. Barnett, Annete Njue, Yu-Jing Huang, Zhanglin Lin Cui & Lee Bowman. (2020) Value of clinical trial narrative data to estimate the costs of adverse event management: a feasibility study. Journal of Medical Economics 23:3, pages 213-220.
Read now
Read now
Alain Vergnenègre & Christos Chouaïd. (2018) Review of economic analyses of treatment for non-small–cell lung cancer (NSCLC). Expert Review of Pharmacoeconomics & Outcomes Research 18:5, pages 519-528.
Read now
Read now
Articles from other publishers (32)
Man Liu, Na Li, Hongzhen Tang, Luohai Chen, Xuemei Liu, Yu Wang, Yuan Lin, Yanji Luo, Shaozhen Wei, Wenli Wen, Minhu Chen, Jiaqian Wang, Ning Zhang & Jie Chen. (2023) The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms. The Oncologist 28:9, pages e723-e736.
Crossref
Crossref
Dong Lin, Shaohong Luo, Shen Lin, Lixian Zhong, Wei Zhou, Dian Gu, Xiaoting Huang, Qixin Chen, Xiongwei Xu & Xiuhua Weng. (2023) Avelumab Maintenance Treatment After First-line Chemotherapy in Advanced Urothelial Carcinoma–A Cost-Effectiveness Analysis. Clinical Genitourinary Cancer 21:1, pages 8-15.
Crossref
Crossref
Chuan Zhang, Jiaxu Zhang, Jing Tan, Panwen Tian & Weimin Li. (2022) Cost-Effectiveness of Pembrolizumab for the treatment of Non–Small-Cell lung cancer: A systematic review. Frontiers in Oncology 12.
Crossref
Crossref
John Hang Leung, Chih-Wen Chang, Agnes LF Chan & Hui-Chu Lang. (2022) Cost–effectiveness of immune checkpoint inhibitors in the treatment of non-small-cell lung cancer as a second line in Taiwan. Future Oncology 18:7, pages 859-870.
Crossref
Crossref
Nan Qiao, Ralph Insinga, Gilberto de Lima Lopes Junior, John Cook & Martin Sénécal. (2021) A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer. PharmacoEconomics - Open 5:3, pages 365-383.
Crossref
Crossref
Edwin Roger Parra, Maria C. Ferrufino-Schmidt, Auriole Tamegnon, Jiexin Zhang, Luisa Solis, Mei Jiang, Heladio Ibarguen, Cara Haymaker, J. Jack Lee, Chantale Bernatchez & Ignacio Ivan Wistuba. (2021) Immuno-profiling and cellular spatial analysis using five immune oncology multiplex immunofluorescence panels for paraffin tumor tissue. Scientific Reports 11:1.
Crossref
Crossref
Yitian Lang, Deshi Dong & Bin Wu. (2020) Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis. Clinical Drug Investigation 40:12, pages 1137-1146.
Crossref
Crossref
Wen-Qian Li, Ling-Yu Li, Ri-Lan Bai, Lei Qian, Nai-Fei Chen & Jiu-Wei Cui. (2020) Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer. Chinese Medical Journal 133:21, pages 2630-2632.
Crossref
Crossref
Erik F. Blom, Kevin ten Haaf & Harry J. de Koning. (2020) Systematic Review and Meta-Analysis of Community- and Choice-Based Health State Utility Values for Lung Cancer. PharmacoEconomics 38:11, pages 1187-1200.
Crossref
Crossref
Charlotte Couchoud, Philippe Fagnoni, François Aubin, Virginie Westeel, Tristan Maurina, Antoine Thiery-Vuillemin, Claire Gerard, Marie Kroemer, Christophe Borg, Samuel Limat & Virginie Nerich. (2020) Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation. Cancer Immunology, Immunotherapy 69:10, pages 1947-1958.
Crossref
Crossref
Haiying Ding, Wenxiu Xin, Yinghui Tong, Jiao Sun, Gaoqi Xu, Ziqi Ye & Yuefeng Rao. (2020) Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review. PLOS ONE 15:9, pages e0238536.
Crossref
Crossref
Shen Lin, Shaohong Luo, Lixian Zhong, Shubin Lai, Dayong Zeng, Xin Rao, Pinfang Huang & Xiuhua Weng. (2020) Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer. International Journal of Clinical Pharmacy 42:4, pages 1175-1183.
Crossref
Crossref
Thierry Berghmans, Valérie Durieux, Lizza E. L. Hendriks & Anne-Marie Dingemans. (2020) Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept. Frontiers in Medicine 7.
Crossref
Crossref
Xiaohui Zeng, Xiaomin Wan, Liubao Peng, Ye Peng, Fang Ma, Qiao Liu & Chongqing Tan. (2019) Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA. BMJ Open 9:12, pages e031019.
Crossref
Crossref
Daniel Gallacher, Peter Auguste, Pamela Royle, Hema Mistry & Xavier Armoiry. (2019) A Systematic Review of Economic Evaluations Assessing the Cost-Effectiveness of Licensed Drugs Used for Previously Treated Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) Negative Advanced/Metastatic Non-Small Cell Lung Cancer. Clinical Drug Investigation 39:12, pages 1153-1174.
Crossref
Crossref
Avirup Guha, Merna Armanious & Michael G. Fradley. (2019) Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. Trends in Cardiovascular Medicine 29:1, pages 29-39.
Crossref
Crossref
Christos Chouaid, Lionel Bensimon, Emilie Clay, Aurélie Millier, Laurie Levy-Bachelot, Min Huang & Pierre Levy. (2019) Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France. Lung Cancer 127, pages 44-52.
Crossref
Crossref
Min Huang, M. Catherine Pietanza, Ayman Samkari, James Pellissier, Thomas Burke, Sheenu Chandwani, Fansen Kong & A. Simon Pickard. (2018) Q-TWiST Analysis to Assess Benefit–Risk of Pembrolizumab in Patients with PD-L1–Positive Advanced or Metastatic Non-small Cell Lung Cancer. PharmacoEconomics 37:1, pages 105-116.
Crossref
Crossref
Vivek Verma, Tanja Sprave, Waqar Haque, Charles B. Simone, Joe Y. Chang, James W. Welsh & Charles R. Thomas. (2018) A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer 6:1.
Crossref
Crossref
Vivek Verma. (2018) Economic sustainability of immune-checkpoint inhibitors: the looming threat. Nature Reviews Clinical Oncology 15:12, pages 721-722.
Crossref
Crossref
C. Chouaid & A. Vergnenègre. (2018) Les coûts du cancer du poumon. Revue des Maladies Respiratoires Actualités 10:3, pages 192-197.
Crossref
Crossref
Renaud Sabatier, Emanuel Nicolas, Maria Paciencia, Annie-Pierre Jonville-Béra, Anne Madroszyk, Maud Cecile, Cecile Braticevic, Ségolène Duran, Louis Tassy, Franck Rouby, Joëlle Micallef & Frédérique Rousseau. (2018) Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer. Journal of Geriatric Oncology 9:5, pages 494-500.
Crossref
Crossref
Hongshu Sui, Ningxia Ma, Ying Wang, Hui Li, Xiaoming Liu, Yanping Su & Jiali Yang. (2018) Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies. Journal of Immunology Research 2018, pages 1-17.
Crossref
Crossref
Geeta Sharma, Ines Mota, Luca Mologni, Enrico Patrucco, Carlo Gambacorti-Passerini & Roberto Chiarle. (2018) Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes. Cancers 10:3, pages 62.
Crossref
Crossref
Mellar P. Davis & Rajiv Panikkar. (2018) Checkpoint Inhibitors, Palliative Care, or Hospice. Current Oncology Reports 20:1.
Crossref
Crossref
Hamzeh Albaba, Charles Lim & Natasha B. Leighl. (2017) Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature. PharmacoEconomics 35:12, pages 1195-1209.
Crossref
Crossref
Di Wu, Chongyang Duan, Fenfang Wu, Liyong Chen & Size Chen. (2017) Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy. Oncotarget 8:39, pages 66491-66503.
Crossref
Crossref
P N AguiarJrJr, L A Perry, J Penny-Dimri, H Babiker, H Tadokoro, R A de Mello & G L LopesJrJr. (2017) The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC. Annals of Oncology 28:9, pages 2256-2263.
Crossref
Crossref
A. Vergnenègre & C. Chouaïd. (2017) Avons-nous les moyens financiers pour l’immunothérapie ?. Revue des Maladies Respiratoires Actualités 9:2, pages 342-347.
Crossref
Crossref
Min Huang, Yanyan Lou, James Pellissier, Thomas Burke, Frank Xiaoqing Liu, Ruifeng Xu & Vamsidhar Velcheti. (2017) Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States. PharmacoEconomics 35:8, pages 831-844.
Crossref
Crossref
Tom MunyerBridgette Kanz Schroader. 2017. PharmacotherapyFirst: A Multimedia Learning Resource. PharmacotherapyFirst: A Multimedia Learning Resource.
Jan Norum, Margareth Aarag Antonsen, Terje Tollåli, Khalid Al-Shibli, Gry Andersen, Kristin Helene Svanqvist & Nina Helbekkmo. (2017) Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis. ESMO Open 2:3, pages e000222.
Crossref
Crossref